Results 51 to 60 of about 2,886,292 (384)

Phosphodiesterase Inhibitors [PDF]

International Cardiovascular Forum Journal, 2019
Phosphodiesterases (PDEs) comprise a superfamily with 11 subfamilies. Within these families, more than 40 isoforms are expressed. Phosphodiesterase-3 inhibitors (PDE3i) are used as inotrope/vasodilators for acute heart failure (HF), and PDE5i for pulmonary hypertension and erectile dysfunction.
Rui Plácido, Mitja Lainscak
openaire   +1 more source

The phosphodiesterase 5 inhibitor sildenafil decreases the proinflammatory chemokine IL-8 in diabetic cardiomyopathy: in vivo and in vitro evidence [PDF]

, 2019
Purpose: Interleukin (IL)-8 is a proinflammatory C-X-C chemokine involved in inflammation underling cardiac diseases, primary or in comorbid condition, such diabetic cardiomyopathy (DCM).
Antinozzi, C., Basili, S., Colletti, M., Corinaldesi, C., Crescioli, C., Di Luigi, L., Filardi, T., Giannattasio, S., Lenzi, A., Morano, S., Scolletta, S.   +10 more
core   +1 more source

Effects of phosphodiesterase inhibitors on secretions of human monokines

Allergology International, 1998
The purpose of this study was to evaluate the effect of newly developed selective phosphodiesterase (PDE) inhibitors, KF19514 (type l/IV) and cilostazol (type III), and theophylline on the secretions of tumor necrosis factor a (TNFα) and interleukin-1β ...
Yuji Suda, Gen Tamura, Isao Ohno, Kimito Maeda, Yi Liu, Kohei Yamauchi, Fumihiko Kurimoto, Kunio Shirato   +7 more
doaj   +1 more source

A pilot study of an oral phosphodiesterase inhibitor (apremilast) for atopic dermatitis in adults.

Archives of Dermatology, 2012
OBJECTIVE To investigate the preliminary safety and efficacy of apremilast, an oral phosphodiesterase 4 inhibitor, for atopic dermatitis. DESIGN This investigator-initiated, open-label pilot study evaluated 2 doses of apremilast in patients with atopic
A. Samrao, Trista M. Berry, Renato Goreshi, E. Simpson   +3 more
semanticscholar   +1 more source

TDP1/TOP1 ratio as a promising indicator for the response of small cell lung cancer to topotecan [PDF]

, 2014
BACKGROUND AND OBJECTIVE Small cell lung cancer (SCLC) is one of the most challenging tumors to treat due to high proliferation rate, early metastatic dissemination and rapid development of chemotherapy resistance.
El-Khamisy, Sherif F, Meisenberg, Cornelia, Schmid, Peter, Ward, Simon E   +3 more
core   +3 more sources

Phosphodiesterase III inhibitor promotes drainage of cerebrovascular β-amyloid

Annals of Clinical and Translational Neurology, 2014
Brain amyloidosis is a key feature of Alzheimer's disease (AD). It also incorporates cerebrovascular amyloid β (Aβ) in the form of cerebral amyloid angiopathy (CAA) involving neurovascular dysfunction.
Takakuni Maki, Y. Okamoto, R. Carare, Y. Hase, Yorito Hattori, C. Hawkes, S. Saito, Yumi Yamamoto, Y. Terasaki, H. Ishibashi-Ueda, Akihiko Taguchi, R. Takahashi, T. Miyakawa, Raj N Kalaria, E. Lo, K. Arai, Masafumi Ihara   +16 more
semanticscholar   +1 more source

Tumor necrosis factor inhibitors in psoriatic arthritis. [PDF]

, 2017
INTRODUCTION: Psoriatic arthritis (PsA) is a chronic inflammatory disease that can result in significant disability. With the emergence of tumor necrosis factor inhibitors (TNFi), therapeutic outcomes in PsA have improved substantially.
Kraft, Walter K., Mantravadi, Santhi, Ogdie, Alexis   +2 more
core   +2 more sources

Presbycusis: Pathology, Signal Pathways, and Therapeutic Strategy

Advanced Science, EarlyView.
In ARHL, the stria vascularis, acting as a cochlear battery, gradually loses its ability to maintain the endocochlear potential, leading to impaired hair cell function and progressive hearing loss. Single‐cell sequencing reveals age‐related cellular changes in the cochlea, providing insights into the underlying mechanisms of aging and potential ...
Xiaoxu Zhao, Tian Shen, Shengda Cao, Ziyi Liu, Wendu Pang, Meixuan Li, Jingjing Liu, Wen Li, Yunhao Wu, Chengcheng Liu, Ming Xia, Xiaolong Fu, Cheng Cheng   +12 more
wiley   +1 more source

Discovery of a Phosphodiesterase 9A Inhibitor as a Potential Hypoglycemic Agent

Journal of Medicinal Chemistry, 2014
Phosphodiesterase 9 (PDE9) inhibitors have been studied as potential therapeutics for treatment of diabetes and Alzheimer’s disease. Here we report a potent PDE9 inhibitor 3r that has an IC50 of 0.6 nM and >150-fold selectivity over other PDEs. The HepG2
Yong-Xian Shao, Manna Huang, W. Cui, Ling-Jun Feng, Yinuo Wu, Yinghong Cai, Zhe Li, Xinhai Zhu, Peiqing Liu, Y. Wan, H. Ke, Hai-bin Luo   +11 more
semanticscholar   +1 more source

Repurposing phosphodiesterase-5 inhibitors as chemoadjuvants [PDF]

Frontiers in Pharmacology, 2013
Phosphodiesterase-5 (PDE5) inhibitors have shown a beneficial effect in a variety of clinical conditions, such as benign prostate hyperplasia, pulmonary arterial hypertension, female sexual arousal disorder, overactive bladder, and incontinence, Raynaud's disease, heart failure and stroke among others (Sandner et al., 2007).
Zhe-Sheng Chen, Amit K. Tiwari
openaire   +4 more sources